As such, it is not surprising that HO-1 is widely expressed in cancer (i.e. glioblastoma, melanoma, bladder, breast, colorectal, renal cancer, prostate) (21) and that its overexpression correlates with cancer invasiveness, resistance to therapies and poor prognosis in different tumors (21–26). Here, HMOX1 is linked to melanoma.